Zheng Nan, Wang Xing, Wang Yaoqi, Xu Guobing, Zhang Hua, Dai Wenbing, He Bing, Zhang Qiang, Ji Jiafu, Wang Xueqing
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Drug Clinical Trial Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Oct 15;1065-1066:96-103. doi: 10.1016/j.jchromb.2017.09.035. Epub 2017 Sep 21.
In recent years, drug conjugates as a prodrug strategy have been widely studied, especially combined with nanotechnology. Disulfide-linked doxorubicin drug-drug conjugate (DOX-S-S-DOX) nanoparticles, have recently been developed as a doxorubicin prodrug nanoparticles with greater anticancer activity and less toxicity than doxorubicin in vivo, while its intracellular kinetics and metabolism is unclear which may provide us with a deeper understanding of its pharmacological mechanism and antitumor effect. Hence, in this study, a rapid and sensitive ultra high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed to detect doxorubicin (DOX) activated from DOX-S-S-DOX, as well as the prodrug itself in human breast cancer tumor cells (MCF-7). Sample preparation involved acetonitrile precipitation to extract the analytes simultaneously and bath sonication to remove intercalated DOX from DNA. The calibration range was 3-60ng/mL for DOX and 20-400ng/mL for DOX-S-S-DOX with the correlation coefficients (r)≥0.99, using daunorubicin as internal standard (IS). The inter- and intra-assay precision (relative standard deviation, RSD%) of quality control samples was in the acceptable range (<15%) and relative error (RE%) for accuracy was between -5.35 and 9.18% for all analytes. Recovery (59.28-69.53% for DOX-S-S-DOX and 99.13-100.10% for DOX) and matrix effect (99.69-111.19%) was consistent, precise, and reproducible at different quality control levels in accordance with FDA guidance. Stability studies showed that DOX-S-S-DOX was unstable both during the bench-top and long-term storage, while the stability during sample preparation and LC-MS runtime was suitable for all the analytes. Hence, the samples should be prepared as soon as possible at the time point to prevent the catabolism of DOX-S-S-DOX. The assay was successfully used in the cellular metabolism and pharmacokinetics study of DOX-S-S-DOX and it may give a clue to explore analytical methods of other prodrug forms of DOX.
近年来,药物偶联物作为一种前药策略受到了广泛研究,尤其是与纳米技术相结合。二硫键连接的阿霉素药物 - 药物偶联物(DOX-S-S-DOX)纳米颗粒,最近被开发为一种阿霉素前药纳米颗粒,在体内比阿霉素具有更高的抗癌活性和更低的毒性,但其细胞内动力学和代谢情况尚不清楚,这可能有助于我们更深入地了解其药理机制和抗肿瘤作用。因此,在本研究中,开发了一种快速灵敏的超高效液相色谱 - 串联质谱(UPLC-MS/MS)方法,用于检测从DOX-S-S-DOX激活的阿霉素(DOX)以及人乳腺癌肿瘤细胞(MCF-7)中的前药本身。样品制备包括用乙腈沉淀同时提取分析物,并通过浴式超声处理从DNA中去除嵌入的DOX。以柔红霉素作为内标(IS),DOX的校准范围为3 - 60ng/mL,DOX-S-S-DOX的校准范围为20 - 400ng/mL,相关系数(r)≥0.99。质量控制样品的批内和批间精密度(相对标准偏差,RSD%)在可接受范围内(<15%),所有分析物的准确度相对误差(RE%)在 - 5.35至9.18%之间。根据FDA指南,回收率(DOX-S-S-DOX为59.28 - 69.53%,DOX为99.13 - 100.10%)和基质效应(99.69 - 111.19%)在不同质量控制水平下是一致、精确且可重复的。稳定性研究表明,DOX-S-S-DOX在台式和长期储存期间均不稳定,而样品制备和LC-MS运行期间的稳定性对所有分析物均合适。因此,应在该时间点尽快制备样品,以防止DOX-S-S-DOX的分解代谢。该方法成功用于DOX-S-S-DOX的细胞代谢和药代动力学研究,可能为探索DOX其他前药形式的分析方法提供线索。